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Background: Platelet function disorders (PFDs) have emerged as an important etiology of heavy menstrual
bleeding (HMB) in adolescents. However, neither clinical nor laboratory data have been methodically analyzed in
this population subset. The objective of this study was to evaluate these parameters in order to distinguish
characteristics of the disorder that in turn will lead to earlier diagnosis and therapy initiation.
Methods: Retrospective review of medical records from postmenarcheal adolescents with documented PFDs
referred to a hemophilia treatment center and university faculty practices for bleeding diatheses with their clinical
and laboratory data evaluated.
Results: Of 63 teens with documented PFDs, HMB was the most common clinical manifestation of PFD (43; 68.3%).
Of these, 37 (86%) were diagnosed with PFD either at or after menarche with the diagnosis based on HMB
symptoms alone. Only 6 (14%) were diagnosed with a PFD prior to menarche, based on associated bleeding, i.e.,
epistaxis, ecchymosis, and all developed HMB after menstruation onset. Interestingly, 20 girls were diagnosed with a
PFD prior to menarche and of these, only 6 (30%) went on to develop HMB after pubertal transition, while the
majority (14; 70%) did not. The average age-at-PFD diagnosis was 14.5yrs, significantly differing from the 10.9yrs
average age-at-PFD diagnosis in their counterparts that, after menarche, did not develop HMB (P<.01) Blood type O
occurred significantly more frequently (76%) than national norms (P <.037). Incidence of δ-Storage Pool deficiency
(δ-SPD) was significantly higher (74%) than their non-HMB cohorts (45%) (P <.007). Coagulation and von Willebrand
factor studies were all normal. Abnormal closure times and aggregation studies were observed in 42% and 60%,
respectively, of tested girls. In 25.6% for whom standard platelet studies were normal, electron microscopy detected
reduced platelet δ-granules numbers (δ-SPD).
Conclusions: Adolescents with PFDs and HMB appear to be clinically distinct from their non-HMB counterparts.
This group of girls is characterized by HMB the major bleeding symptom, significantly high incidences of blood
group O and the δ-SPD with a PFD diagnosed well after menarche. High false negative standard platelet function
study results indicate additional diagnostic strategies, particularly for δ-SPD, should be considered.
Keywords: Platelet function disorders, Adolescents, Heavy menstrual bleeding, Menorrhagia, δ-Storage Pool
Deficiency (δ-SPD)* Correspondence: lsamesse@mvh.org
1Division of Reproductive Endocrinology and Infertility, Department of
OB-GYN, Section of Pediatric-Adolescent Gynecology, Wright State University
Boonshoft School of Medicine, Dayton, OH, USA
2Division of Pediatric Hematology & Oncology, Department of Pediatrics,
Wright State University Boonshoft School of Medicine, Dayton, OH, USA
Full list of author information is available at the end of the article
© 2013 Amesse et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Amesse et al. Experimental Hematology & Oncology 2013, 2:3 Page 2 of 12
http://www.ehoonline.org/content/2/1/3Background
Abnormal uterine bleeding is a common problem in the
adolescent population, where it affects up to 37% of teen-
age girls [1,2]. The bleeding etiology in this age group is
often attributed to anovulatory menstrual cycles subse-
quent to immaturity of the hypothalamic-pituitary-
ovarian axis [3,4]. However, in nearly one half of all cases
a definitive etiology remains elusive [5-13]. Hemostatic
disorders such as von Willebrand disease (VWD) and
single coagulation factor deficiencies have been impli-
cated as important etiologies for many years.
Platelet function disorders (PFDs)–a heterogeneous
group of inherited, qualitative platelet defects--have re-
cently emerged as a frequent, equally important cause of
abnormal uterine bleeding in adolescents. In this popula-
tion subset, PFDs often manifest as heavy menstrual
bleeding (HMB), formerly termed menorrhagia, defined
as menstrual blood loss >80mL per menses [1,4-7,9-17].
However, platelet dysfunction-associated HMB has not
been methodically analyzed in adolescents, and there is
limited published objective data on the disorder. For the
last decade, a total of only 2 communications have
examined in detail the clinical and laboratory features of
platelet dysfunction-associated HMB in teenagers, and
for both studies, data was obtained from a total of 10
adolescents combined [5,7]. Indeed, most reports on
HMB intermixed demographic data from adolescents
with PFDs with either similarly affected adults or adoles-
cents having disparate hematologic disorders, without
exclusively evaluating adolescents with PFDs and HMB
[4,6,8-16,18]. Other reports and case series were pre-
dominately composed of patients diagnosed with syn-
dromic platelet disorders, e.g., Bernard Soulier syndrome,
Glanzmann’s thrombasthenia, or idiopathic thrombocy-
topenic purpura [4,19,20].
Platelets are integral components of primary hemostasis.
Upon vascular injury, von Willebrand factor (VWF) med-
iates platelet adherence to the exposed subendothelial
matrix. Platelets are then activated and secrete the contents
of their alpha (α) and dense (δ) granules and other fac-
tors, i.e., thromboxane A2, platelet activating factor. The
secreted factors in turn interact with specific platelet
receptors to mediate activation and recruitment of add-
itional platelets that bind to the adhered platelets, forming
aggregates that lead to the formation of a hemostatic plug.
Inherited PFDs can be classified according to their
functional defects, although clear distinctions are not
always evident. Defects can involve platelet secretion
(e.g. α-, δ-granule storage pool deficiencies); signal trans-
duction pathways (e.g. arachidonic acid, thromboxane
A2); signal transduction receptors (e.g., thromboxane A2,
collagen); and platelet adhesion receptors (e.g., glycopro-
tein Ia/IIa). Of these, the dense (δ) granule storage pool
deficiency (SPD) is the most common.A wide range of specialists evaluate young girls pre-
senting with HMB. The initial evaluation includes a
careful history with directed attention to personal and
familial bleeding tendencies. Pertinent examination find-
ings include petechiae and ecchymosis. These teenagers
should undergo platelet testing concurrent with VWF
assays. Initial laboratory studies include complete blood
count (CBC) with platelet counts and morphology, pro-
thrombin time (PT), activated partial thromboplastin
time (aPTT) and fibrinogen or thrombin and VWF
tests for VWD diagnosis [ristocetin cofactor (VWF:
RCo), VWF antigen (VWF:Ag), VWF:RCo / VWF:Ag
ratios and factor VIII activity (F VIII:C)]. However, no
single laboratory test can diagnose all platelet disorders
and consultation with a hematologist is often indicated.
Rapid, accurate diagnosis of PFDs in young girls clinic-
ally manifesting HMB is crucial to initiation of appropri-
ate therapy that in turn prevents severe bleeding,
emergent hospitalizations, blood transfusions and bleed-
ing at surgery. Early detection also mitigates the negative
impact HMB has on an adolescent’s education as well as
reduced lifestyle and quality of life parameters [9].
In this communication we focus exclusively on a
subset of adolescents with documented PFDs and a
physician diagnosis of HMB. Here we report on vari-
ous clinical and laboratory findings that offer novel
insights into the early natural history of the disorder.
These data provide a foundation for understanding
platelet dysfunction-associated HMB in this population
subset that will aid in it’s earlier recognition, diagnosis
and therapeutic initiation.
Results
Seventy-one young females with objectively documented
PFDs were initially identified; 8 were disqualified for rea-
sons of menarche not achieved (6) and failure to return
for follow-up visits (2). The study population was com-
posed of a cohort of 63 postmenarcheal adolescents with
bleeding symptoms and documented PFDs. Their clin-
ical and laboratory profiles are summarized in Table 1.
Clinical features
Heavy menstrual bleeding was the most common clinical
manifestation of a PFD, 68%, (n=43) (HMB group).
Thirty-two percent (n=20) had neither documentation
nor a physician diagnosis of HMB after pubertal transi-
tion (non-HMB group). Of the 43, 86% were diagnosed
with a PFD after menarche based on heavy menstrual
bleeding symptoms, while only 14% were diagnosed with
a PFD prior to achieving menarche. Of the 14%, platelet
function studies were initiated based on associated
bleeding symptoms, including epistaxis, easy bruisability,
surgery-associated bleeding, etc. A total of 20 patients
were diagnosed with a PFD prior to achieving menarche
Table 1 Clinical and laboratory characteristics at presentation for postmenarcheal adolescents with documented
platelet function disorders
Clinical & Laboratory Characteristics Heavy Menstrual Bleeding (n=43) Non-Heavy Menstrual Bleeding (n=20) P
Age (y) at PFD diagnosis (mean; range) 14.5 ± 3.5; 3 - 20 10.9 ± 3.5; 5 - 17 <.01
Prior to menarche 6 (14) 14 (70)
At menarche 10 (23) 0
After menarche 27 (63) 6 (30)
Age (y) at menarche (mean; range) 11.8 ± 1.0; 9 - 15 12.1 ± 1.5; 9 - 16 .36
Interval (y): PFD-dx-to menarche (mean) 2.54 ± 3.09 1.48 ± 3.11 <.01
after menarche prior to menarche
Age (y) at HMB onset (mean; range) 13.5 ± 1.9; 9 - 18 0
At menarche 10 (23) 0
After menarche 33 (77) 0
Interval (y): from menarche-to-HMB onset (mean; range) 1.79 ± 1.4; 0–5.0 0
PBAC score ≥ 100 43 (100) 0
Ethnicity
Caucasian 35 (81) 16 (80) 1.0
African-American 4 ( 9) 1 (5)
Asian 1 ( 2) 0
Hispanic 1 ( 2) 1 (5)
Multiethnic 2 ( 5) 2 (10)
Family History of Bleeding Tendencies
Positive 36 (83.7) 17 (85) .41
Negative 7 (16.3) 3 (15)
ABO Rh(D) ABO Rh(D)
Blood Group Types + − + −
Group O 33 (76.0) 27 6 14 (70.0) 13 1 .037†
Group A 9 (21.0) 9 0 6 (30.0) 6 0
Group B 1 ( 3.0) 1 0 0 0 0
Hematocrit (%) (mean)* 37.3 ± 4.8 38.0 ± 3.9 .7
MCV (fL) (mean)* 85.4 ± 5.1 86.0 ± 5.9 .75
Platelet count (μ/L) (mean) 284.0 ± 62.3 285.0 ± 71.0 .99
PT (s) (mean) 12.2 ± 0.81 12.5 ± 0.94 .35
aPTT (s) (mean) 31.8 ± 6.3 31.4 ± 4.0 .82
ABO-Adjusted VWF Levels
von Willebrand Factor Assays‡ O A,B O A,B
VWF:RCo (%) (mean) 69.7±18.7 91.9±16.2 84.5±21.2 101.2±29.6 .13
VWF:Ag (%) (mean) 88.0±10.3 100.7±13.6 88.3±10.1 104.0±24.6
FVIII:C (%) (mean) 119.0 ± 66.7 104.0 ± 27.9
VWF:RCo/VWF:Ag ratio (mean) 0.912 ± 0.235 0.960 ± 0.274
aPTT=activated partial thromboplastin time; dx=diagnosis; FVIII:C=Factor VIII activity; MCV=mean corpuscular volume; PT= prothrombin time;VWF=von Willebrand
factor; VWF:RCo=ristocetin cofactor activity; VWF:AG=VWF antigen; PBAC=pictorial bleeding assessment chart; U.S.=United States.
Data for both groups are presented as means ± standard deviations or n (%).
*Reference intervals (females) at corresponding ages ≤13yrs or >14yrs:Hematocrit, 35-45% or 37-47%; MCV, 78-95fL or 78-100fL; platelet count, 140,000-450,000μ/L.
†P-value applies only to ABO blood group distribution differences between HMB-group & a comparable U.S. population.21,22 ‡von Willebrand Factor Assay
reference intervals adjusted for blood groups O & A,B: A,B:VWF:RCo=37.5-117.1 & 48 206.1;VWF:Ag=48.1-146 & 50.7-193.7, respectively.
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6 (14) 20 (100)
Number of bleeding
symptoms per patient
one 15 (35) 11 (55)
two 23 (53) 5 (25)
three or more 5 (12) 4 (20)
Other PFD-associated bleeding symptoms:
Epistaxis 18 (64) 14 (70)
Easy bruisability 16 (57) 10 (50)
Post operative bleeding
associated with:
8 (29) 6 (30)







Not specified 1 1
Gingival and/or oral mucosa 2 (4) 1 (5)
Hematuria 0 1 (5)
PFD=platelet function disorder P-values exceeded 0.05 for all differences
between the two groups.
Data for both groups are presented as n (%).
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while the majority (13; 70%) did not develop HMB after
menarche (median follow-up, 42mo). The average age-
at-PFD diagnosis in patients affected with HMB was
14.5 years, with later age at diagnosis based on HMB the
sole bleeding symptom in 86%, significantly differing
from the average age-at-PFD diagnosis, 10.9 years,
observed in PFD patients that did not develop HMB
after menarche (P<.01).
Later age-at-PFD diagnosis is also observed when the
menarche is considered a point of reference. The inter-
val from age-at-PFD diagnosis to age-at-menarche in
adolescents affected with HMB was on average 2.5 years
after menarche, significantly at variance with the (mean)
1.5 years prior to menarche observed in patients that
did not manifest HMB after pubertal transition. (P<.01).
There were no significant differences between the 2
groups in (mean) age at menarche (P=.36).
Onset of HMB occurred at (mean) age 13.5 years
with the interval between menarche-to-HMB onset
(mean) 1.8 years, indicating that for a large majority, 33
(77%), HMB occurred after experiencing several men-
strual cycles.
Caucasian (80-81%) was the most common ethnicity.
Additional ethnicities in descending order of frequency
included African American, “Multiethnic,” Hispanic and
Asian. Over 80% of participants gave family histories
positive for bleeding tendencies. No significant differ-
ences between the 2 groups were identified with respect
to these parameters (P>.05).
Laboratory features
Type O was the most common blood group and there
were no significant differences identified between inter-
group ABO-Rh(D) phenotypic frequencies (P>.05). How-
ever, teenagers affected with PFDs had ABO blood types
that were at a significant variance with a comparable
Caucasian U.S. population. The 70-76% type O fre-
quency observed in our PFD teens occurred more fre-
quently than the 44-45% reported for an analogous
national population, while types A and B occurred less
frequently. Type A was found in 20.9%-30% of our PFD
adolescents compared with 40-42% reported for national
Caucasian norms; type B, detected in only 0–2.3% versus
11% nationally (P=.037) [21,22]. The AB blood group,
noted in 4% of the United States population, was not
expressed by any PFD patients.
Adolescents with PFDs that manifested HMB were not
anemic; the (mean) hematocrits, hemoglobin levels (not
shown) and MCVs, all fell within normal ranges for their
respective ages, ≤ 13yrs or >14yrs, and gender. Platelet
counts and morphologic examination, coagulation stud-
ies and VWF studies for VWD diagnosis all fell within
normal ranges for their respective ABO blood groupswith no significant differences identified between the two
groups for these parameters (P>.05). Abnormal VWF
tests were recorded in only 1 adolescent (HMB group)
diagnosed with combined PFD-VWD, type I. Factor II
(1), V (1), VII (1), IX (1), XI (9) and XII (8) levels per-
formed in selected patients all fell within normal ranges
(not shown).
Bleeding profile
The nature and number of bleeding symptoms at pres-
entation for all postmenarcheal adolescents with docu-
mented PFDS are shown in Table 2. Heavy menstrual
bleeding was the only presenting symptom in 37 (86%)
of the HMB group. The majority 28 (65%) experienced
additional bleeding symptoms, with 1 patient reporting 5
different symptoms. Additional bleeding included epi-
staxis (18; 64%), easy bruisability (16; 57%), surgery-
associated bleeding (8; 29%), and gingival and/or mucosa
bleeding (2; 4%). Only 6 (14%) presented with non-HMB
bleeding symptoms and all did such prior to menarche.
Non-HMB adolescents with PFDs shared a similar
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fied between both groups with respect to the nature
or the number of bleeding symptoms (P>.05).
Platelet function studies
Abnormal testing results from platelet studies—prolonged
closure times using the platelet function analyzer (PFA)
system and impaired platelet aggregation by light transmis-
sion aggregometry (LTA)—and electron microscope (EM)
detection of reduced platelet δ-granule numbers are sum-
marized in Table 3 for both groups [7,11-13,23-26]. The
majority of teens, 26 (60.5%), affected with HMB had one
abnormal platelet study, while 17 (39.5%) had 2 abnormal
studies. Similar results were observed in non-HMB adoles-
cents: 14 (70%) and 6 (30%), 1 and 2 abnormal platelet
studies, respectively. No patient had 3 abnormal platelet
studies. The reciprocal observation indicated that 11
(25.6%) and 2 (10%) of HMB and non-HMB patients, re-
spectively, had normal platelet function studies and for
these patients, EM detection of diminished storage pool
granule numbers was the only study that identified a plate-
let disorder. EM also identified similar findings in 14.3% of
teens with HMB that had single agonist defects on platelet
aggregation studies.
Platelet function analyzer
Prolonged closure times by the PFA system, collagen-
epinephrine (C-EPI) >143s and/or collagen-adenosine
diphosphate (C-ADP) >106s, were observed in 18
(41.9%) and 10 (50%) of HMB and non-HMB patients,
respectively, with no significant differences identified be-
tween the 2 groups (P=.17). Patients were subsequently
diagnosed with a PFD based on LTA and/or EM results.
Light transmission aggregometry
LTA studies were variable, with no definitive aggregation
pattern emerging, even among adolescents sharing similarTable 3 Abnormal platelet testing and electron microscopy st
Prolonged Closure Times* Impaired Plat
Patient Group C-EPI, C-ADP EPI
(n=43)
Heavy Menstrual Bleeding 18 (41.9) 14 (40.0)
(n=20)
Non-Heavy Menstrual Bleeding 10 (50) 15 (75)
AA=arachidonic acid; C-EPI=collagen-epinephrine; C-ADP=collagen-ADP; DG/PL=den
diphosphate; epi=epinephrine.
P-values exceeded 0.05 for all differences between the 2 groups.
Data are presented as n (%).
Closure times were performed on platelet function analyzer system; Aggregation st
enumeration was performed by whole mount EM of platelet samples.
*Prolonged closure times=2 S.D. above mean RI:C-EPI, 86-143s & C-ADP, 59-106s; Impair
0.5μM (78.1-99.8%),10μM (82.8-100.3%); AA:0.5mmol/L (75.6-102.8%); Collagen: 2.0μ
Ristocetin:0.5mg/mL (0.0-21.7%), 1.15mg/mL (75.9-107.1%),1.37mg/mL (80.1-104.9%
§Based on available aggregation studies.clinical and laboratory profiles. Overall, 21 of 35 (60.0%)
tested HMB adolescents had reduced maximal platelet ag-
gregation with ≥1 agonists. Of the 21, most (16; 45.7%) had
multiple agonist-induced aggregation defects: 8 teens to 2
agonists and another 8 to 3 agonists, while 5 (14.3%) had a
single agonist abnormality. In the non–HMB group, 15
(75%) had abnormal platelet aggregation to ≥1 agonists. Of
these, 13 (65%) had multiple agonist defects: 7 patients to
2 agonists, 4 to 3 agonists, and 2 to 4. Only 2 (10%) had a
single agonist defect. LTA was normal with all 5 agonists
for 14 (40%) and 5 (25%) HMB and non-HMB patients,
respectively.
The most common agonists to elicit abnormal platelet
responsiveness in both patient groups were epinephrine
(60 μM and/or 150 μM) followed by ADP (5 μM and/or
10 μM), while collagen (2 μg/mL and/or 5 μg/mL) was
the least common. Additional agonist-induced aggregation
defects occurred in the majority of HMB and non-HMB
teens (64-93% epinephrine; 70-86% ADP), respectively, with
only occasional isolated epinephrine (17-36%) and ADP
(14-30%) defects.
Ristocetin (1.15 mg/mL and/or 1.37 mg/mL)-induced
aggregation abnormalities uniformly occurred with add-
itional agonist-induced defects in 8 (22.9%) and 5 (25%)
HMB and non-HMB adolescents, respectively, and did
not occur as an isolated impairment. The 0.5 mg/mL ris-
tocetin did not adversely influence platelet aggregation
in either group. Patients with the ristocetin defect were
predominately Caucasian and VWF tests for VWD diag-
nosis were all normal [27]. Impaired arachidonic acid
(AA) (0.5 mmol/L)-induced responsiveness was found in
5 (14.3%) HMB and 7 (35%) non-HMB adolescents, with
all 12 diagnosed with aspirin-like-defect (ALD). The ALDs
were not subtyped according to defects in the AA-pathway.
However, 2 of the 12 adolescents with absent AA-induced
responsiveness had impaired aggregation with other ago-
nists and preserved ristocetin responsiveness, suggesting audies in adolescents with platelet function disorders
elet Aggregation Responsiveness by Agonist* EM Reduced DG/PL*
ADP Ristocetin AA Collagen <3.68 DG/PL
(n=35§) (n=28)
10 (28.6) 8 (22.9) 5 (14.3) 2 (5.7) 26 (92.9)
(n=20) (n=6)
7 (35) 5 (25) 7 (35) 1 (5.0) 6 (100)
se granules per platelet; EM=electron microscope; ADP= adenosine
udies were performed by light transmission aggregometry; Dense granule.
ed aggregation=2 S.D. below mean RI for each agonist's concentration: ADP:
g/mL(75.8-110.0%), Epi:60μM, (76.6-107.5%), 150μM (78.9-107.1%);
). Normal dense granule numbers per platelet: 4–6.
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cent had an isolated AA defect. There were no significant
differences between the groups with respect to aggregation
responsiveness for any of the 5 agonists (P>.05).
Electron microscopy
EM detected significantly reduced platelet δ-granule num-
bers, <3.68DG/PL, in 26 (92.9%) of 28 tested HMB adoles-
cents, while normal δ-granule numbers (4-6DG/PL) were
calculated in 2 (7.1%) [Figure 1]. All 6 (100%) tested non-
HMB adolescents had diminished platelet δ-granule num-
bers. EM identified one patient with the combined α-δ
storage pool defect.
Types of platelet defects
Platelet defect types are shown in Table 4 for both adoles-
cent groups. Adolescents diagnosed with HMB had a sig-
nificantly greater incidence, 32 (74%), of the δ-SPD than
teens that did not manifest HMB (9; 45%) after menarche.
Indeed, the proportion of the δ-SPD was 1.64-fold higher
(RR 1.64, 95% CI 1.06, 2.92) and the prevalence odds ratio
(OR) of the δ-SPD was 4.62-fold higher among HMB PFD
teens than in their non-HMB counterparts (98% CI 1.47,
14.5, P=.007). The next most common PFD type was the
ALD, diagnosed in 5 and 7 HMB and non-HMB PFD
teens, respectively. One adolescent from each group was
diagnosed with combined δ-SPD-ALD and one (HMB
group) had the combined α-δ SPD. There were no cases of
absent δ- or α-granules, as found in classic, syndromic
platelet disorders, e.g., Hermansky-Pudlak Syndrome or
gray platelet syndrome, respectively.
Discussion
Platelet function disorders are a heterogeneous group of
inherited bleeding defects with bleeding severity rangingFigure 1 Transmission electron micrographic image of a
normal platelet with 8 dense (δ) granules evident (whole
mount EM, unstained; 10,000X).from mild to severe. While some patients may be asymp-
tomatic, most present with ecchymosis, epistaxis, HMB or
excessive bleeding associated with surgical procedures or
trauma. The present retrospective study includes the lar-
gest reported series on adolescents that clinically manifest
HMB due to platelet function disorders (n=43). The study
methodically evaluates in this population subgroup various
clinical and laboratory characteristics not previously exam-
ined. Data from the study offer novel insights into the early
natural history of the disorder that will assist in its
characterization as well as earlier identification.
Observations from the present study intriguingly sug-
gest that adolescents with PFDs that manifest HMB after
menarche represent a clinically distinct phenotype from
similarly affected teenagers that do not develop HMB
after pubertal transition. Indeed the possibility that
intra- and intergroup differences exist at the genomic or
proteomic levels and these differences influence variable
phenotypic bleeding manifestations is supported by the
finding of a significantly higher incidence of the δ-SPD
(74%) in adolescents with HMB when compared with
non-HMB teenagers (P<.007).
The incidence of HMB was considerable among ado-
lescents with documented PFDs. It was the most com-
mon bleeding symptom, manifesting in over two-thirds
(68%) of young females affected with PFDs. Both the
(mean) age-at-PFD diagnosis and the presenting symp-
tomatology differed between the 2 groups. Young girls
that developed HMB after menarche were significantly
older when they were diagnosed with a PFD—by 3.6yrs—
when compared with non-HMB teens (P<.01). Indeed, a
significant majority (86%) were diagnosed with a PFD at or
after the menarche based on HMB symptoms, while 14%
were rendered a PFD diagnosis prior to the menarche
based on associated bleeding, e.g., epistaxis, ecchymosis,
etc. (P<.01) Overall, only 30% of patients diagnosed with a
PFD prior to menarche subsequently manifested HMB
after pubertal transition, and all had the δ-SPD, while a
large majority (70%) did not develop HMB after menarche
(42mo median follow-up).
Significant differences between age-at-PFD diagnoses
may in part reflect bleeding severity. Individuals with se-
vere bleeding symptoms often present early in child-
hood, suggesting patients that did not manifest HMB
after menarche presented with more severe bleeding that
led to earlier evaluation and diagnosis [28]. Some may
have had family members with positive bleeding histor-
ies, prompting earlier evaluation. However, owing to the
heterogeneity of PFDs, it is possible that some may not
have manifested as severe bleeding symptoms as other
patients with de novo PFD diagnoses, but without posi-
tive familial bleeding histories. Additionally, our HMB
teens shared a similar high prevalence of family bleeding
tendencies and yet were diagnosed with a PFD at an
Table 4 Types of platelet defects identified in postmenarcheal adolescents








δ-SPD 32 (74) 9 (45) 0.007 4.62 (1.47,14.5)
Combined δ-SPD + Aspirin-like
defect
1 ( 2) 1 ( 5) >.05
Combined α-δ-SPD 1 ( 2) 0 >.05
Aspirin-like defect 4 ( 9) 6 (30) >.05
Platelet function disorder, NFC 4 ( 9) 4 (20) >.05
Combined PFD and type I, VWD 1 ( 2) 0 >.05
α=alpha; δ-SPD=dense granule Storage Pool deficiency; NFC=not further classified; VWD=von Willebrand Disease.
Data are presented as n (%).
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ence earlier PFD diagnoses as evidenced by similar inter-
group surgery-associated bleeding histories, particularly
childhood tonsillectomies and adenoidectomies. Treat-
ment regimens, such as desmopressin acetate, tranex-
amic acid, etc., may have prevented HMB. However,
therapeutic intervention does not explain the existence
in our study of a subset of young girls diagnosed with a
PFD prior to menarche (14%) that developed HMB after
transitioning into puberty. Indeed, similar findings were
recently reported in a study by Chi et al. in which the
diagnosis of a bleeding disorder was known in 64% of
young females prior to their presentation with menor-
rhagia, yet they developed HMB despite instruction to
take tranexamic acid when menses began [14].
The long (mean) 1.8-year interval between menarche-
to-HMB onset was at variance with prior studies on
menorrhagia that reported HMB occurring predomin-
ately at or within the first year of menarche in patients
with bleeding disorders [4,6,7,9]. Indeed, Chi et al.
reported HMB onset occurred at menarche in 90% of
adolescents affected with bleeding disorders [14]. Ado-
lescents with PFDs that clinically manifested HMB have
not been exclusively analyzed until the present report. It
is possible that differences in the menarche-to-HMB
interval may be related in part to prior studies intermix-
ing data from PFD patients with data from subjects
affected with disparate bleeding disorders, thus obscur-
ing the actual temporal relationship [4,5,7,14]. Of inter-
est, PFD adolescents that clinically manifested HMB
were not anemic. For these patients, the menarche was a
recent event with the PFD diagnosis rendered close to
the menstruation onset. This may have aided in earlier
treatment initiation that may have in turn mitigated
heavy bleeding and subsequent anemia.
A substantial number of adolescents with PFDs, 70-
76%, had blood type O, intriguingly paralleling the 77%
type O frequency reported for VWD, type I individuals
[29,30]. Indeed, the high blood type O phenotypic fre-
quency was an unexpected finding and to our knowledge
has not been previously reported. When examined inthe context of a comparable U.S. population, blood
group O occurred in our PFD adolescents significantly
more frequently and types A and B, less frequently
(P<.037) [21,22]. Prior studies on menorrhagia have
reported type O blood occurring in 44-59% of their
patients, paralleling national norm frequencies, despite
their inclusion of numerous VWD females [8,9,11,12].
Blood type O individuals have VWF levels approximately
25% lower than non-type O individuals. Our patients
had normal ABO-adjusted VWF testing with only one
patient, with combined PFD-VWD, type I showing VWF
studies diagnostic for VWD diagnosis. The mechanism
for the preponderance of blood group O, in the absence
of VWD in our PFD adolescents is unknown [29,30]. In-
deed, mechanisms influencing blood group O on plasma
VWF levels are elusive. Variable VWF carbohydrate
structures have been associated with lowered VWF
levels in blood group O individuals. Additionally, blood
group O individuals have significantly higher rates of
VWF proteolysis by the metalloproteinase, a disintegrin
and metalloproteinase with thrombospondin motif,
member 13 (ADAMTS13) when compared with non-O
individuals [31]. Genetic differences in ADAMTS13
levels may also influence VWF clearance in type O blood
groups. Lower VWF levels (not diagnostic for VWD) as
reported in blood type O individuals, combined with
functional platelet defects, particularly the δ-SPD, may
represent an additional variable adversely affecting
hemostasis that renders PFD-blood type O individuals
more vulnerable to bleeding than PFD patients expres-
sing A, B blood types.
The significant association between adolescents with
HMB and PFD, particularly the δ-SPD, suggests that
blood type O may be a useful identifier for these disor-
ders and may assist clinicians in stratifying patients for
additional studies. Certainly, blood typing is not
intended to serve as a screening test for bleeding disor-
ders. However, if blood typing has been performed, data
from our study indicate adolescents presenting with
HMB that express blood type O, have normal coagula-
tion profiles and ABO-adjusted VWF tests for VWD,
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or impaired by a single agonist defect may benefit from
additional EM studies to exclude the δ-SPD. Without a
definitive diagnosis, such as that offered by EM, many
patients with this disorder may go undetected.
Prior reports and data from our study indicate that
standard platelet screening by closure times (PFA sys-
tem) and LTA have moderate sensitivity in detecting and
diagnosing PFDs, particularly the δ-SPD [15,26,32-36].
The Hayward et al. 2006 report of a survey on published
literature regarding PFA efficacy concluded that the test
lacked adequate sensitivity in screening for platelet dis-
orders [32]. Philipps and coworkers studied the utility of
closure times (PFA) and bleeding times in screening for
bleeding disorders in women with HMB. Their data
indicated the PFA had a sensitivity of 23%, specificity of
92%, positive predictive value of 75% and a negative pre-
dictive value of 52% in women with PFDs [35]. Cattaneo
et al. studied closure time (PFA system) and bleeding
time effectiveness in patients with δ-SPDs and platelet
secretion defects and concluded that both tests per-
formed with similarly low sensitivity [36]. Data from
these reports supports our finding of high false negative
closure times.
Platelet LTA, considered the “gold standard” for diag-
nosing PFDs, has well-known limitations [26,37]. The
issue of whether single agonist-induced aggregation
defects can accurately detect a PFD is a potential limita-
tion. Most patients with PFDs, 29.7% - 30.3%, in 2 prior
studies on HMB had single agonist defects identified by
platelet aggregation studies. In our study, the majority
(45.7%) of HMB patients had multiple agonist-induced
aggregation defects, while only 14.3% had a single agon-
ist abnormality and our non-HMB group showed similar
testing results. Hayward et al. reported that reduced
maximal aggregation with >1 agonists significantly
increases PFD detection [12,15,38]. Miller et al. recently
addressed the criterion of >1 agonist defects and the
subject of multiple statistical comparisons used in plate-
let function testing. The authors noted that had the >1
agonist criterion been applied in their study, 30.3% of
patients would have been excluded, as would those
patients affected with a single platelet receptor defect to
one agonist (e.g., collagen, ADP) [15]. In our study,
14.3% of HMB patients with single agonist defects would
have been similarly excluded, all of whom were diag-
nosed with the δ-SPD by EM. Indeed, these 5 patients
with the following LTA single agonist defects: 0.5 μM
ADP (3); 60 μM epinephrine (1); and 0.5 mmol/L AA
(1) all had significantly reduced platelet δ-granules on
EM. Miller et al. appropriately cautioned against render-
ing a PFD diagnosis on the basis of a single test [15].
However, some patients with the δ-SPD have single
agonist aggregation defects, as identified in 14.3% in ourstudy, as well as normal aggregation studies. Nieuwenhuis
et al. reported on 106 patients with platelet disorders with
25% having normal platelet aggregation studies and all
were subsequently diagnosed with the “SPD” by total
platelet ADP and serotonin testing [33]. Israels et al.
similarly reported on a subset of 15 patients with
normal aggregation studies subsequently diagnosed with
“platelet storage pool deficiency” by EM and ATP release
testing [34]. These studies parallel our findings. Indeed,
the δ-SPD diagnosis would have been missed in an
additional 25.6% and 10% of our HMB and non-HMB
teenagers, respectively, that had normal standard platelet
function studies (closure times by PFA; LTA) and for
whom EM studies revealed significantly reduced platelet
δ-granule numbers.
EM may be indicated in some cases as a confirma-
tory method for detecting diminished granule numbers
[23-26,34]. Although not widely available, other diag-
nostic studies for the δ-SPD, such as flow cytometry of
mepacrine uptake, are similarly not widely available.
Clinical judgment should be rendered; as previously stated,
data from our study indicate that young girls with HMB,
normal coagulation profiles and ABO-adjusted VWF tests
for VWD, blood type O, and normal or single agonist
defects on platelet function studies, would be excellent
candidates for EM studies for detecting the δ-SPD. EM
studies are done at a number of centers. Excellent distinc-
tions between normal and diminished δ-granule numbers
have been reported among those institutions included in a
recent study by Hayward et al. [26].
Limitations to the study include those common to
retrospective reports. There was an absence of an ado-
lescent control group with unexplained HMB after ex-
clusion of all non-hematologic etiologies. We sought in
part to define the clinical profile of PFD adolescents at
presentation and no attempts were made to correct for
PBAC changes over time and after treatment. Sanitary
products were not standardized and this is an infrequent
limitation [4-8,11-15]. A small minority of HMB patients
did not have platelet LTA results recorded, with only
observed data used in the analyses and this is an infre-
quent occurrence [4,5]. The potential for selection bias
in our specialist-referred patient population and cases
sent for EM cannot be excluded. A potential confounder
is whether timing of platelet samples sent for EM either
during or shortly after a hemostatic challenge affected
δ-granules numbers. Exhausted platelet granules would
be expected to adversely influence platelet aggregation
studies, yet 40% of adolescents with reduced δ-granule
numbers on EM had normal platelet aggregation stud-
ies. Despite these limitations, detailed clinical and la-
boratory data obtained from the study has assisted in
defining the characteristics of adolescents with platelet
dysfunction-associated HMB that have never before been
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future longitudinal cohort studies. Additionally, these data
will aid clinicians in earlier diagnosis of the disorder and
will alert them to select additional platelet testing, such as




Retrospective review of medical records of young females
with documented PFDs referred to the West Central Ohio
Hemophilia Treatment Center and pediatric-adolescent
gynecology faculty practices at Dayton Children’s Medical
Center and the Miami Valley Hospital for evaluation and
routine follow-up for bleeding diatheses between June
1998 and June 2009. Institutional Review Boards at the
centers approved the study and patient confidentiality was
protected according to HIPAA guidelines.
Collected demographic information included: age at PFD
diagnosis; age at presentation; age at menarche; age(s) at
onset of HMB and/or other bleeding symptoms; ethnicity;
medical and surgical histories; family history of bleeding
tendencies; medication history; physical examination; la-
boratory studies; consultations; and radiographic and/or
other diagnostic studies. Records were also reviewed for a
physician’s diagnosis and clinical history of HMB along
with supporting documentation, including assessment of
menstrual blood loss using the PBAC. Physical examin-
ation findings and laboratory studies were scrutinized for
any tangible manifestations or biochemical changes asso-
ciated with anovulation and/or polycystic ovary syndrome
including, but not limited to, hirsutism, acne and/or
obesity as well as clinical phenotypes associated with syn-
dromic platelet disorders. Patients with any laboratory
studies suggestive of an existing endocrine disorder or
any other known medical condition, iatrogenic anticoagu-
lation, medications interfering with platelet function or
anatomical defects that resulted in HMB were excluded.
Records from postmenarcheal patients with documented
PFDs were set aside for further consideration.
The study population was composed of a cohort of post-
menarcheal adolescents evaluated for bleeding diatheses
and rendered a diagnosis of PFD between ages (range) 3.0-
20.17 years. Patients were followed at 6-month intervals
for up to 11 years with 42 months the median duration.
Patients were evaluated and stratified into 2 groups based
on the presence or absence of a physician’s diagnosis of
HMB and supporting documentation. Patient stratification
allowed in patients affected with the similar disease process
of platelet dysfunction investigation of both disparate and
common characteristics that would assist in distinguishing
the disorder of platelet dysfunction-associated HMB.
At menarche, all patients were interviewed regarding
the menstrual cycle and were provided with standardinstitutional menstrual booklets that included PBACs.
The booklets were returned and reviewed by one
hemophilia center nurse coordinator (ND) at each visit
as previously described [39]. Briefly, patients were not
provided with pads or tampons, but were instructed on
proper methods for recording the menses duration and
interval; estimation of blood loss and clot sizes; the
number of disposed pads and/or tampons used per men-
ses; and PBAC completion. The PBAC semi-quantitative
scoring system was used to approximate menstrual
blood loss, with a score ≥100 corresponding to >80 mL
of menstrual blood loss per cycle and correlates with the
definition of HMB [22,23]. While spectrophotometric
analysis of alkaline hematin at 450 nm is considered the
gold standard for quantifying menstrual blood loss, the
PBAC is a reasonable, uncomplicated and validated
method that is often used [40,41]. Patient histories of HMB
were recorded; documentation consisted of a recorded
mean PBAC score ≥100. Mean PBAC scores <100 were
not in accordance with a HMB diagnosis. Two attending
physicians (JAF, LSA) or a hemophilia center nurse coord-
inator (ND) reviewed all PBAC scores.
Laboratory studies
All blood samples were obtained using standard phlebot-
omy techniques. Hemostatic testing was performed by one
specialized coagulation laboratory. Hematologic studies for
all patients were conducted as previously published [21].
Briefly, initial testing consisted of: CBC with platelet count
and examination of platelet morphology, PT, aPTT, ABO-
Rh(D) blood group typing, fibrinogen, VWF:RCo, VWF:Ag,
VWF:RCo / VWF:Ag ratios and FVIII:C. Selected patients
underwent single coagulation factor II, V, VII, IX, XI and/
or XII activity levels. Patients with normal platelet counts
and morphology, ABO-adjusted ranges for VWF levels, co-
agulation studies, fibrinogen levels and single coagulation
factor activity levels underwent platelet function studies
and/or subsequent electron microscopy (EM) quantifica-
tion of platelet dense (δ) granules or qualitative investiga-
tion of alpha (α) granules.
Platelet function studies
Patients were instructed to avoid prostaglandin inhibi-
tors and all other medications interfering with platelet
function for 10-14d prior to platelet studies.
Platelet function analyzer closure times
Whole blood samples were collected in 3.2% citrate and
processed within 2hrs of collection. Closure times (CTs)
using the platelet function analyzer system (PFA-100W,
Dade Behring, Inc., Miami, Florida) were conducted on
patient samples with C-EPI and C-ADP coated cartridges
with respective reference intervals (RIs), 86-143sec and
59-106sec. RIs were obtained from normal females that
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tions 10-14d prior to testing and were determined as
2 standard deviations (S.D.) about the mean. Normal
controls were run with each new cartridge lot and
testing was performed in duplicate. Closure times
were considered prolonged, with either one (C-EPI
or C-ADP) or both cartridges, when the results were
more than 2 S.D. above the mean and repeat testing
confirmed the abnormality.
Light Transmission Aggregometry
Light transmission aggregometry was performed on
platelet-rich plasma (PRP) using the PACKS-4 aggreg-
ometer (Helena Laboratories Corp., Beaumont, Texas)
and specimens were processed within 3hrs of collec-
tion. Activation of PRP was performed in accordance
with the manufacturer’s guidelines and spontaneous
platelet aggregation was observed. RIs were calculated
as 2 S.D. about the mean in normal female controls.
The following agonists were added at the stated final
concentrations included with their respective RIs for
maximal percentage of platelet aggregation: adenosine
diphosphate (ADP), 0.5 μM (78.1-99.8%) and 10 μM
(82.8-100.3%); arachidonic acid (AA), 0.5 mmol/L (75.6-
102.8%); collagen 2.0 μg/mL (75.8-110.0%) and 5.0 μg/mL
(83.3-103.2%); epinephrine, 60 μM (76.6-107.5%) and
150μM (78.9-107.1%); and ristocetin, 0.5 mg/mL (0.0-
21.7%,), 1.15 mg/mL (75.9-107.1%) and 1.37 mg/mL
(80.1-104.9%). Maximal percentage for platelet aggregation
responsiveness was measured over 10min duration. Platelet
LTA studies were considered impaired when maximal ag-
gregation responsiveness was reduced more than 2 S.D.
below the lower RI with ≥1 agonists. Test results were
reported as either in range or out of range, with all LTA
tracing examined by one hematologist (JAF).
Patients having normal results from platelet function
studies (closure times by PFA; LTA) or a single agonist-
induced aggregation defect on LTA together with a
strong clinical suspicion of an underlying bleeding dis-
order and/or a family history positive for bleeding ten-
dencies were selected to undergo platelet EM studies.
Electron microscopy
EM studies on patient platelet samples were assessed for
quantitatively reduced δ-granules and qualitative α-granule
reduction. Whole mount EM morphologic examination
was used to quantify of platelet δ-granules. Collected sam-
ples were prepared by placing one drop of citrated-PRP on
parlodian-coated grids for 5min followed by 2 distilled
water rinses. Filter paper was used to blot excess fluid from
the grid edge. After air-drying at room temperature, plate-
lets were examined by one expert (WTG) using a FEI Tec-
nai transmission EM (FEI, Hillsboro, Oregon) without
fixation or staining.Classification of δ- and α-granules was based on mor-
phological parameters elucidated by Weiss et al. and
White et al. [23,24]. Platelet α-granules were investigated
qualitatively. Enumeration of δ-granules was performed
as previously described [24,25]. The mean number of
δ-granules identified in 100 contiguous platelets was
reported. Dense granule (DG) diameters were deter-
mined and DG mean volume (v = 4/3r3) was calcu-
lated from at least 10 platelets (30–100 DGs analyzed).
The total volume of dense granules (TDGV) per plate-
let was determined by multiplying the mean dense
granule volume (DGV) × dense granule number (DGN)
[25]. Significantly reduced mean δ-granules/platelet
(DG/PL) numbers and/or total δ-granule volume/platelet
(TDGV/PL) were calculated as <3.68 DG/PL or <8.0 ×
106fL, respectively, from that determined in normal
female controls (4–6 DG/PL or 8–12 × 106fL) [23-25].
Diagnostic criteria for a PFD included reduced max-
imal platelet aggregation responsiveness with ≥1 ago-
nists 2 S.D. below RI on LTA in the absence of
platelet function-interfering medications and/or EM
detection of reduced δ-granules numbers, or near ab-
sent α-granules with replacement vacuolization. The
δ-SPD was rendered in some cases only by EM stud-
ies [11,12,23-26]. Diagnostic criteria for the aspirin-
like defect (ALD) included absent to significantly
reduced (≤10%) AA-induced platelet responsiveness,
irrespective of additional epinephrine and/or ADP-
induced aggregation abnormalities.
Statistical Analysis
All data from postmenarcheal adolescents with documen-
ted PFDs, one group diagnosed with HMB and the other
without a HMB diagnosis, were analyzed using SAS statis-
tical package, version 9.2 (SAS Institute, Inc., Cary, North
Carolina). The means and S.D. for ages at PFD diagnosis,
menarche, and HMB; intervals from age-at-PFD diagnosis
to age-at-menarche and age-at-menarche-to-age-at-HMB
onset; and laboratory testing parameters were calculated.
RIs for platelet testing were calculated as 2 S.D.s about the
mean for normal female controls as previously stated. For
continuous variables, a t-test was used to compare the
means between the two groups. The Χ2 test was used for
categorical variables to determine whether an association
existed between the two groups. A finding was considered
statistically significant if P was ≤.05. Odds ratios (OR) and
95% confidence intervals (CIs) were used to compare the
δ-SPD prevalence between both groups.
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